What is the core product of Senmotion?

Based on the visual evidence on Slide 1 and Slide 13, the core product is a sensor-embedded shoe insole. This hardware is designed to capture high-precision motion data, which is then transmitted to a smartphone and processed via an AI/ML analytics engine to provide diagnostics and therapy recommendations for musculoskeletal disorders.

How does Senmotion differentiate itself from consumer wearables like the Apple Watch?

Slide 10 uses a 2x2 matrix to position Senmotion in the top-right quadrant, representing the highest 'Sensors/Data Quality' and 'Medical' relevance. The deck argues that consumer brands like Apple, Fitbit, and Huawei lack the medical specificity and data precision required for clinical diagnostics in musculoskeletal health.

What is the primary market pain point addressed in the deck?

The deck focuses on the economic and clinical burden of Musculoskeletal Disorders (MSD). Slide 4 notes that MSD is the second leading cause of early retirement and the largest cost center in rehabilitation, resulting in €34 billion in annual costs in Germany alone.

Who are the key members of the leadership team?

The team is led by co-CEOs Ilja Solomonovs (Management/Strategy) and Prof. Dr. Thomas Ertelt (Biomechanics/Data Analytics). They are supported by Prof. Dr. Thomas Gronwald, who handles intervention and therapy, and CTO Dimitri Biermann, a Senior Software Architect (Slide 2).

What information is missing from this pitch deck?

The deck is missing several standard venture capital requirements: a clear revenue model, a go-to-market strategy, unit economics for the hardware, a roadmap for regulatory approval, and a specific funding ask. It functions more as a clinical and technical overview than a complete investment proposal.

Senmotion Pitch Deck: 13-Slide Breakdown

See all 13 slides of the Senmotion pitch deck, with a slide-by-slide teardown of what the deck does well and where it falls short.

Senmotion's 2019 pitch deck focuses on the massive economic burden of musculoskeletal disorders (MSD), citing €34 billion in annual costs in Germany alone. The company proposes a '360° Solution' that combines IoT wearable insoles with AI/ML analytics to provide high-precision diagnostics and personalized therapy. While the deck successfully establishes a strong academic team—featuring two professors specializing in biomechanics and training science—and highlights a significant gap in current wearable accuracy, it lacks critical business details. There is no mention of unit economics, manufact…

Key takeaways

The company targets musculoskeletal disorders (MSD), which they claim affect 80% of people at least once in their lives (Slide 4).
Senmotion identifies a €34 billion annual cost for MSD in Germany and over 1.1 million knee and hip procedures per year in the US (Slide 4).
The technical solution relies on high-precision sensors in wearables combined with a 'Scientific Pattern Database' for AI/ML analytics (Slide 6).
A performance graph compares Senmotion's accuracy against the 'Goldstandard' AMTI and competitors Pedar and Moticon, suggesting existing systems are inaccurate (Slide 8).
The team is heavily academic, featuring two CEOs, one of whom is a Professor for Biomechanics and Motion Science (Slide 2).
Senmotion positions itself in the high-quality, high-medical-relevance quadrant, above competitors like Fitbit, Apple, and Withings (Slide 10).
The deck provides no financial projections, revenue model, or go-to-market strategy beyond general 'telemedicine care' mentions (Slide 6).
There is no specific investment ask or information regarding the current stage of product development or clinical trials (Slide 13).

Slide-by-Slide Teardown

Slide 1: Title Slide

The title slide introduces Senmotion with a clear subtitle: "high-precision sensors as IoT wearables - combined with AI-controlled diagnostics for digital health solutions of the future." The background image shows the physical product—a pair of red and black insoles—alongside a smartphone displaying the company logo. This immediately establishes the company as a hardware-enabled software play (MedTech/IoT). The year 2019 is clearly marked at the bottom.

Slide 2: Excellent Team

The team slide highlights a strong academic and technical foundation. It features four key members: Ilja Solomonovs (CEO, Dipl. BWL), Prof. Dr. Thomas Ertelt (CEO, Prof. for Biomechanics & Motion Science), Prof. Dr. Thomas Gronwald (Intervention and Therapie), and Dimitri Biermann (CTO, Senior Software Architect). The inclusion of two professors suggests a deep focus on the scientific validity of the data analytics, which is crucial for a medical-grade wearable. However, having two CEOs can sometimes be a red flag for investors regarding decision-making clarity.

Slide 4: MSD - Musculoskeletal disorders

This is the "Problem" slide. It uses high-level statistics to quantify the market opportunity. Key figures include: 80% of people get sick with MSD at least once, there are more than 150 clinical pictures , and it is the second leading cause of early retirement . The most striking figure is the €34 billion p.a. cost in Germany alone. By citing over 1,167,000 knee & hip TEP procedures per year in the US, the deck establishes a massive Total Addressable Market (TAM) for diagnostic and post-operative monitoring tools.

Slide 6: Our 360° Solution

This slide outlines the workflow of the Senmotion ecosystem. It starts with Wearables: Motion Data combined with Individual data and Scientific studies . These feed into a Scientific Pattern Database , which is then processed by AI/ML Analytics . The output is categorized into three buckets: Unique data & high-precision diagnostics , Personalized Therapy & Prevention , and Telemedicine care and effectiveness . This slide effectively explains how the hardware (insoles) serves as the data entry point for a larger software platform.

Slide 8: No accurate system available today

This is a technical validation slide. It features a graph comparing Kraft [N] (Force) against Zeit [s] (Time). The red line (presumably Senmotion, though not explicitly labeled as such in the legend) is shown tracking closely with the AMTI (Goldstandard) , while competitors Pedar and Moticon are shown as significantly less accurate or having different force profiles. This slide is intended to prove that existing mobile solutions are insufficient for clinical use, creating a "moat" based on data precision.

Slide 10: Excellent opportunity

This is the competitive positioning matrix. The Y-axis represents Sensors/Data Quality and the X-axis represents Medical relevance. Senmotion places itself in the top-right corner. Competitors like Huawei and Xiaomi are in the bottom-left (consumer/low quality). Apple , Fitbit , and Withings are in the center (consumer/medium quality). dorsaVi , Verily , and Evidation are positioned closer to the medical axis but lower in sensor quality than Senmotion. This is a bold claim that would require significant technical backing during due diligence.

Slide 13: Contact

The final slide repeats the product imagery and provides contact information for Ilja Solomonovs , including an email, mobile number, and website. Notably, there is no "Ask" on this slide or the preceding ones. Investors are left not knowing how much capital the company is seeking or what the specific milestones for the next round of funding would be.

What Works Well

Clear Problem Quantification: Slide 4 does an excellent job of using hard numbers (€34 billion cost, 1.1M procedures) to prove that the problem is worth solving. · Academic Credibility: The presence of two professors in relevant fields (Biomechanics and Training Science) on Slide 2 gives the "AI/ML Analytics" claims much-needed weight. · Visual Product Identification: The deck consistently shows the product, making it clear that this is a tangible hardware solution, not just a theoretical software concept. · Technical Comparison: Using a force/time graph (Slide 8) to compare against a laboratory gold standard (AMTI) is a highly effective way to communicate technical superiority to a technically-literate investor.

What Is Missing

The Ask: The most significant omission is the lack of a funding request. There is no mention of how much money is being raised, the valuation, or the use of proceeds. · Business Model: The deck explains what the product does but not how the company makes money. Is it a hardware sale, a SaaS subscription for clinics, or a per-patient diagnostic fee? · Regulatory Roadmap: For a product claiming "high-precision diagnostics" and "medical" relevance, the absence of CE Mark or FDA clearance status is a major gap. · Traction: There are no mentions of pilot programs, hospital partnerships, or current user numbers. The deck feels very early-stage/pre-revenue. · Go-to-Market Strategy: While it mentions telemedicine, it doesn't explain how they will acquire customers in a notoriously difficult healthcare sales environment.

What a Founder Should Copy

The 2x2 Matrix Logic: Even if the positioning is aggressive, the axes chosen (Data Quality vs. Medical Relevance) are exactly what a MedTech investor cares about. · Problem-Solution Alignment: The transition from Slide 4 (the cost of MSD) to Slide 6 (the 360° solution) is logical and easy to follow. · Professional Design: The deck uses a consistent color palette (red, black, white) and high-quality product photography, which helps build brand trust. · Focus on Data Integrity: In the crowded wearable space, focusing on accuracy relative to a lab standard (Slide 8) is a better differentiator than focusing on features .

Frequently asked questions

What is the core product of Senmotion?: Based on the visual evidence on Slide 1 and Slide 13, the core product is a sensor-embedded shoe insole. This hardware is designed to capture high-precision motion data, which is then transmitted to a smartphone and processed via an AI/ML analytics engine to provide diagnostics and therapy recommendations for musculoskeletal disorders.
How does Senmotion differentiate itself from consumer wearables like the Apple Watch?: Slide 10 uses a 2x2 matrix to position Senmotion in the top-right quadrant, representing the highest 'Sensors/Data Quality' and 'Medical' relevance. The deck argues that consumer brands like Apple, Fitbit, and Huawei lack the medical specificity and data precision required for clinical diagnostics in musculoskeletal health.
What is the primary market pain point addressed in the deck?: The deck focuses on the economic and clinical burden of Musculoskeletal Disorders (MSD). Slide 4 notes that MSD is the second leading cause of early retirement and the largest cost center in rehabilitation, resulting in €34 billion in annual costs in Germany alone.
Who are the key members of the leadership team?: The team is led by co-CEOs Ilja Solomonovs (Management/Strategy) and Prof. Dr. Thomas Ertelt (Biomechanics/Data Analytics). They are supported by Prof. Dr. Thomas Gronwald, who handles intervention and therapy, and CTO Dimitri Biermann, a Senior Software Architect (Slide 2).
What information is missing from this pitch deck?: The deck is missing several standard venture capital requirements: a clear revenue model, a go-to-market strategy, unit economics for the hardware, a roadmap for regulatory approval, and a specific funding ask. It functions more as a clinical and technical overview than a complete investment proposal.

Cover slide of the Senmotion pitch deck — Senmotion pitch deck, slide 1

Senmotion pitch deck: the facts

Company: Senmotion
Slides: 13

Senmotion pitch deck PDF

The full Senmotion deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Senmotion pitch deck was used for

This deck is Senmotion GmbH’s NOAH19 Berlin conference pitch deck from June 2019, presenting their hardware-plus-software solution of sensor-embedded insoles and AI diagnostics for musculoskeletal disorders. It positions Senmotion as a digital health startup using high‑precision IoT wearables and motion data analytics for telemedicine, personalized therapy, and rehabilitation. The deck appears aimed at early-stage investors and partners, highlighting technology, clinical use cases, and market opportunity rather than specific funding round terms. No externally verifiable information links this specific deck to a disclosed funding amount or named investors.

Business model: Developer of sensor-based motion-tracking insoles and software for medical movement and stress analysis, enabling quantitative diagnosis, monitoring and therapy evaluation for musculoskeletal conditions.

Founders: Ilja Solomonovs
Headquarters: Berlin, Germany (Mühlenstraße 8A, 14167 Berlin).
Industry: Digital health / medical monitoring equipment (sensor-based gait and load analysis).

What the Senmotion deck got right

Compelling hardware–software integration for quantitative motion diagnostics. Senmotion’s product concept combines **high-precision sensor insoles** with a motion-analysis software application that quantifies ground reaction forces and movement, enabling objective assessment of musculoskeletal load and therapy effectiveness.
Platform vision across diagnostics, telemedicine and rehabilitation. The NOAH19 Berlin deck description and separate pitch materials emphasize a **360° digital health solution** that integrates telemedicine, personalized therapy and rehabilitation around unique sensor technology, positioning Senmotion as a platform rather than a single device.
Clear focus on musculoskeletal and movement-disorder use cases. External profiles describe Senmotion’s insoles being used to diagnose and monitor musculoskeletal conditions and support therapy evaluations, aligning closely with a large, clearly defined clinical need in movement and posture disorders.
Alignment with IoT, AI and connected-health investment themes. The product is framed as an **IoT wearable** with AI-controlled diagnostics, plugged into mobile devices for clinicians, which matches investor interest in scalable, connected-health solutions and continuous data streams.
Founder story supports credibility in the smart insole niche. Media coverage of founder Ilja Solomonovs specifically highlights his creation of sensor-equipped insoles to assess and correct musculoskeletal function, reinforcing perceived founder-market fit and domain focus.
Differentiation through objective, load-specific motion data. Pitch materials and descriptions emphasize the ability to provide **load-specific data and movement profiles** that go beyond traditional, often qualitative musculoskeletal assessments, which is a strong differentiator versus non-instrumented therapy.

What could have been stronger

Lack of visible traction metrics in publicly described deck. Publicly available descriptions of the NOAH19 Berlin deck emphasize Senmotion’s technology and telemedicine ambitions but do not show any slide content on concrete traction metrics, such as current user numbers, clinical deployments, revenue, or growth KPIs, which limits an investor’s ability to assess market validation from the deck alone.
Very broad solution scope without a clearly articulated initial focus. The Slideshare and external pitch deck references describe a broad solution—from high‑precision insoles to AI diagnostics, telemedicine, therapy personalization and rehabilitation—without clearly articulated focus on one primary initial beachhead segment, which may make the commercial path and early go‑to‑market strategy hard to infer from the deck.
Limited externally visible validation details (benchmarks, regulatory status). Although Senmotion’s insoles are described as measuring ground reaction forces and providing quantitative movement data, the available descriptions of the deck do not provide technical performance benchmarks (accuracy versus gait labs, reliability, or regulatory status), limiting how convincingly the deck can substantiate clinical-grade claims for investors.
Business model and monetization not clearly detailed in available deck description. Neither the NOAH19 deck description nor public profiles include any explicit information on the business model specifics—pricing, reimbursement pathways, or whether Senmotion charges per insole, per analysis, or via SaaS to clinics—so investors reviewing only this deck must infer monetization rather than seeing it laid out.

How an investor would read this deck

What draws attention

Unique positioning at the intersection of **smart insoles**, **quantitative motion analysis**, and **digital health / telemedicine** with a clear clinical use case in musculoskeletal disorders.
Strong emphasis on **high-precision sensor hardware** combined with **AI-driven diagnostics and therapy optimization**, which aligns with trends towards objective, data-driven rehabilitation and remote monitoring.
Berlin-based team with a founder (Ilja Solomonovs) highlighted in media coverage for building sensor-based insoles for musculoskeletal assessment, suggesting founder-market fit in this niche.
Platform-style vision that can extend from clinical gait and load analysis into broader telemedicine, personalized therapy, rehabilitation, and potentially sports and occupational health use cases.

Risks that stand out

Regulatory and clinical risk if the insoles and analytics are marketed for diagnosis or therapy decisions without sufficiently strong validation, regulatory clearance, or alignment with medical device regulations.
Competitive risk from other smart insole and gait-analysis solutions that already operate in clinical and research settings, making differentiation and adoption challenging without clear evidence of superior performance or workflow integration.
Execution risk in translating a broad, platform-style vision (insoles, AI diagnostics, telemedicine, therapy personalization, rehabilitation) into a focused, commercially viable initial product line and repeatable sales model.
Reimbursement and adoption risk in convincing payers, clinics, and therapists to change established gait-analysis and rehabilitation workflows, particularly if the economic case (cost savings, improved outcomes) is not clearly quantified in the deck.

Questions this deck invites

What specific **clinical validation** has been completed for Senmotion’s insoles and analytics (e.g., trials comparing accuracy to force plates or gait labs, published studies, regulatory approvals)?
How is the **business model** structured—who pays (clinics, insurers, employers, patients), what is the pricing logic (hardware sale, SaaS subscription, per-analysis fee), and are there reimbursement codes or contracts already in place?
What is the current **traction** in terms of active customers (clinics, hospitals, therapists), number of monitored patients, and recurring revenue, and how does this compare to competing smart-insole and gait-analysis solutions?
What is Senmotion’s **data and AI strategy**—how are motion data sets collected, labeled, and used to train diagnostic algorithms, and what protections exist around data privacy, security, and regulatory compliance?
How defensible is the technology versus other smart insoles and motion-tracking platforms (patents, proprietary sensor designs, algorithms), and what are the key **go-to-market channels** (clinical partners, device distributors, telemedicin

What founders can take from the Senmotion deck

A pitch deck for a medical hardware-plus-software startup can effectively differentiate the product by emphasizing **quantitative, high-precision data** and clearly describing how that data supports diagnosis, monitoring, and therapy decisions.
Positioning sensor-based insoles as part of a broader **digital health platform**—including telemedicine, personalized therapy, and rehabilitation—helps investors see long-term scalability beyond the initial device.
Explicitly connecting a novel wearable technology to **prevalent, high-burden conditions** such as musculoskeletal disorders and posture-related problems strengthens the perceived market opportunity.
Combining references to **AI-driven diagnostics** with intuitive clinical workflows (e.g., clinicians receiving clear movement and load profiles on mobile devices) can make complex technology more understandable and investable.
Early-stage decks benefit from highlighting the **founder’s background and motivation**, especially when media or third-party profiles reinforce their focus on the specific clinical problem they aim to solve.
Even when a deck is strong on technology narrative, investors still expect concrete details on traction, validation, and monetization; their absence becomes a visible weakness and a key focus of due diligence.

Senmotion pitch deck: common questions

What does Senmotion do?

Senmotion is a Berlin-based digital health startup that develops sensor-embedded insoles and accompanying software to measure ground reaction forces, movement and stress, providing quantitative motion and load data for diagnosing and monitoring musculoskeletal conditions.

What is the Senmotion NOAH19 Berlin pitch deck about?

Senmotion presented this pitch at the NOAH Berlin Conference 2019, held June 13–14, 2019 at STATION Berlin. The deck focuses on their high‑precision IoT wearables, AI-driven diagnostics and digital therapy solutions for musculoskeletal and related health issues.

How does Senmotion’s product work in practice?

According to a company profile, Senmotion offers a sensor-based device placed in or on a shoe that measures ground reaction forces on the sole and provides load-specific movement data, visualized via a mobile software application for medical professionals. The Slideshare description adds that their solution extends into telemedicine, personalized therapy, and rehabilitation supported by AI diagnostics.

Has Senmotion raised funding for the product shown in this deck?

Publicly accessible information describes Senmotion’s motion-tracking insoles and software and lists its Berlin office, but does not disclose specific funding amounts, investors, or rounds. Major databases and the NOAH19 materials do not show a clearly identified round tied to this deck, suggesting that if fundraising occurred, the terms were not publicly announced.

Who founded Senmotion and what problem are they solving?

A media profile notes that founder Ilja Solomonovs, who moved from Latvia, started the Senmotion startup in Berlin to produce innovative insoles with sensors for assessing and correcting the musculoskeletal system. Together with the pitch deck description, this suggests a focus on both diagnosis and therapy optimization for conditions such as musculoskeletal disorders and posture-related problems.

Sources

Funding and outcome facts on this page were researched on 2026-08-22 from the pages below.

Senmotion pitch deck slides

Senmotion pitch deck slide 1 of 13 — Senmotion pitch deck — slide 1 of 13

Senmotion pitch deck slide 2 of 13 — Senmotion pitch deck — slide 2 of 13

Senmotion pitch deck slide 3 of 13 — Senmotion pitch deck — slide 3 of 13

Senmotion pitch deck slide 4 of 13 — Senmotion pitch deck — slide 4 of 13

Senmotion pitch deck slide 5 of 13 — Senmotion pitch deck — slide 5 of 13

Senmotion pitch deck slide 6 of 13 — Senmotion pitch deck — slide 6 of 13

What each slide of the Senmotion pitch deck says

Slide 3

Excellent Team ~~ ™M a TY h £ \ J \ ( { | | \ | A ) \ y Ilia Solomonovs Prof. Dr. Thomas Ertelt Prof. Dr. Thomas Gronwald Dimitri Biermann CEO CEO Intervention and Therapie CTO Dipl. BWL, Responsible Prof. for Biomechanics & Prof. Training and Motion Senior Software Architect, for management and Motion science, responsible for science, responsible for responsible for technical strategy Data Analytics treatment solutions product development | Senmotion GmbH - Pich Deck 2

Slide 4

Great growth potential in the digital health market ~~ | 2017 488. |r” : sa ail Ea - [A | + =|n 2017, US $ 5.8 billion was -— / bs invested in Digital Health startups $1.28 a LA #4 flatiron Roche $1.98 = US Mega-Deals in Q1 2018: ABILITY inowson $1.28 intermedix RT RCM Inc. $460M | Senmotion GmbH - Pitch Deck 3

Slide 5

MSD - Musculoskeletal disorders: affects almost everyone ~~ ™M = About 80% of people get sick at least once in their lives = More than 150 clinical pictures and syndromes Costs of € 34 billion p.a. = Second leading cause of early retirements by MSD in Germany only! = Largest cost center in REHA = Over 1,167,000 knee & hip TEP procedures per year in US | Senmotion Gr - ich Deck 4

Slide text above is read directly from the Senmotion deck PDF embedded on this page.

Related fundraising guides (24)

Browse companies alphabetically (1)

Pitch decks from companies starting with S

More pitch deck teardowns (16)

Recently published pitch deck teardowns (12)

Fundraising library · Pitch deck examples · Investor directory · Founder database